BUSINESS

• Daiichi Sankyo, US Research Institute to Collaborate in Developing Cardiovascular-Metabolic Disease Treatments
  May 26, 2014

• 3 More SGLT-2 Inhibitors Make Japan Debuts to Trail Suglat
  May 26, 2014

• Astellas Launches Anticancer Drug Xtandi Capsules in Japan
  May 26, 2014

• Three Companies Including DSP Jointly Invest 845 Million Yen in Create Vaccine
  May 26, 2014

• Teikoku Seiyaku Licenses Antiallergic Treatment from Uriach of Spain
  May 26, 2014

• Foreign Drug Makers’ Japan Units Underperform Market Growth in 2013
  May 23, 2014

• Blopress AG Rollout Won’t Coincide with June Listing: ASKA Pres.
  May 23, 2014

• 5 of 17 Pharmacy Chains Settle April-June Delivery Prices via Qol-Led Open Tender
  May 23, 2014

• Teva Pharma Japan to Postpone NHI Price Listing of All Generics Including Valsartan in June
  May 23, 2014

• JPMA Code Committee to Discuss Actions against Kyowa Kirin, Novartis over Improper Involvement in Clinical Trials
  May 22, 2014

• Takeda’s UC, CD Treatment Entyvio Approved in US
  May 22, 2014

• EPS Did Nothing Wrong in Data Verifications for VART Study Probe: Pres.
  May 21, 2014

• AZ to Highlight Global Data to Push Forxiga: Primary Care Head
  May 21, 2014

• Towa Wins Japan’s 1st Approval for Viagra Generic
  May 21, 2014

• Improper Staffer Involvement in 4 More Japan CML Programs: Novartis
  May 20, 2014

• Medipal Holdings Sets 2,253 Billion Yen Goal for FY2016 Ethical Drug Wholesaling Sales
  May 20, 2014

• Daiichi Sankyo to Revise Its Midterm Business Plan Due to Transfer of Ranbaxy
  May 20, 2014

• Sales of 25 Major Japan Drug Makers Up 10% as Top 4 Pharmas’ Offshore Revenues Flourish
  May 19, 2014

• Blopress Generic to Go on Sale after June Listing, Japan’s 1st AG to Hit Shelves Before Rivals
  May 19, 2014

• RaQualia, Kyoto University, iPS Academia Japan Announce Joint Research Agreement
  May 19, 2014

ページ

• « 先頭
• ‹ Prev
• …
• 545
• 546
• 547
• 548
• 549
• 550
• 551
• 552
• 553
• …
• Next ›
• 最終 »